for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NicOx SA

NCOX.PA

Latest Trade

4.43EUR

Change

-0.07(-1.45%)

Volume

58,385

Today's Range

4.42

 - 

4.48

52 Week Range

4.30

 - 

7.15

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Nicox Reports Positive Results Of Secondary Analyses From Phase 2 Trial Of NCX 470

Oct 22 (Reuters) - NICOX SA <NCOX.PA>::REG-NICOX REPORTS POSITIVE RESULTS OF SECONDARY ANALYSES FROM PHASE 2 TRIAL FURTHER HIGHLIGHTING POTENTIAL OF NCX 470 IN GLAUCOMA.PHASE 3 CLINICAL PROGRAM EXPECTED TO BE INITIATED IN Q2 2020 WITH 0.065% AND 0.1% DOSES, PENDING END-OF-PHASE 2 MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).NCX 470 SHOWED IMPROVED IOP LOWERING WITH EACH INCREMENTAL CONCENTRATION OF NCX 470 TESTED, SETTING STAGE FOR POTENTIALLY FURTHER IOP LOWERING AT A HIGHER DOSE.NCX 470 0.065% PRODUCED SIGNIFICANTLY SUPERIOR INTRAOCULAR PRESSURE (IOP) LOWERING COMPARED WITH LATANOPROST 0.005% IN SECONDARY ANALYSES.

Nicox Q3 Net Revenue Up At 0.5 Million Euros

Oct 16 (Reuters) - NICOX SA <NCOX.PA>::Q3 2019 NET REVENUE OF EUR 0.5 MILLION.POSITIVE TOPLINE RESULTS FROM DOLOMITES PHASE 2 CLINICAL TRIAL OF NCX 470 IN GLAUCOMA.IN Q3 VYZULTA PRESCRIPTIONS EXCEEDED 3,000 PER WEEK FOR FIRST TIME.AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €17.4 MILLION.NICOX AMENDED ITS BOND FINANCING AGREEMENT WITH KREOS CAPITAL AND DREW DOWN EUR 4 MILLION IN ADDITIONAL DEBT..AS OF SEPTEMBER 30, 2019, THE NICOX GROUP HAD FINANCIAL DEBT OF €7.4 MILLION IN THE FORM OF A BOND FINANCING AGREEMENT WITH KREOS CAPITAL SIGNED IN JANUARY 2019..NICOX MAY DRAW DOWN A FURTHER EUR 3 MILLION OR EUR 8 MILLION ON DECEMBER 31.

Nicox Amends Bond Agreement With Kreos, Draws Down Further 4 Million Euros

Oct 10 (Reuters) - Nicox SA <NCOX.PA>::NICOX AMENDS BOND FINANCING AGREEMENT WITH KREOS AND DRAWS DOWN ADDITIONAL €4 MILLION.NICOX MAY NOW DRAW DOWN A FURTHER EUR 3 MILLION OR EUR 8 MILLION ON DECEMBER 31, 2019, SUBJECT TO NOTICE TO KREOS BY DECEMBER 16, 2019.

Nicox H1 Net Loss Lowers To EUR 0.8 Mln

Sept 17 (Reuters) - Nicox SA <NCOX.PA>::H1 2019 NET REVENUE (1)OF EUR 5.6 MILLION AND NET LOSS (2)OF EUR 0.8 MILLION.ENROLLMENT COMPLETED IN NCX 470 PHASE 2 DOLOMITESCLINICAL TRIAL IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION. TOP-LINE RESULTS ON TRACK FOR EARLY Q4 2019.H1 NET LOSS FOR THE PERIOD EUR 0.8 MILLION VERSUS LOSS OF EUR 7.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 5.3 MILLION VERSUS LOSS OF EUR 8.7 MILLION YEAR AGO.H1 LOSS BEFORE TAX EUR 4.6 MILLION VERSUS LOSS OF EUR 7.6 MILLION YEAR AGO.AS OF JUNE 30, 2019, NICOX GROUP HAD FINANCIAL DEBT OF €7.4 MILLION IN THE FORM OF BOND FINANCING AGREEMENT WITH KREOS CAPITAL SIGNED IN JANUARY 2019.TOP-LINE RESULTS OF NCX 4251 PHASE 2 CLINICAL TRIAL ON TRACK FOR Q4 2019.AS OF JUNE 30 CASH AND CASH EQUIVALENTS OF €17.3 MILLION.

Nicox Q2 Net Revenue Up At EUR 5.2 Million

July 17 (Reuters) - Nicox SA <NCOX.PA>::NICOX: SECOND QUARTER 2019 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.ENROLLMENT COMPLETED IN NCX 470 PHASE 2 CLINICAL TRIAL IN PATIENTS WITH GLAUCOMA AND OCULAR HYPERTENSION WITH RESULTS EXPECTED IN EARLY Q4 OF THIS YEAR.Q2 2019 NET REVENUE, INCLUDING LICENSING PAYMENTS, OF EUR 5.2 MILLION.TOTAL NUMBER OF PRESCRIPTIONS FOR VYZULTA IN U.S. IN Q2 OF 2019 INCREASED BY 17% COMPARED TO Q1 2019.AS OF JUNE 30, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €17.3 MILLION.

Nicox Announces Completion Of Enrollment In NCX 470 Phase 2 Clinical Study

July 16 (Reuters) - Nicox SA <NCOX.PA>::PRIMARY ENDPOINT OF STUDY IS MEAN REDUCTION IN DIURNAL IOP AFTER 28 DAYS OF TREATMENT (REMOVES EXTRANEOUS TEXT).REG-NICOX ANNOUNCES COMPLETION OF ENROLLMENT IN NCX 470 PHASE 2 CLINICAL STUDY WITH TOP-LINE RESULTS ON TRACK FOR EARLY 4Q 2019.TOP-LINE DATA OF STUDY ARE EXPECTED EARLY IN Q4 OF THIS YEAR.OVERALL OBJECTIVE IS TO IDENTIFY APPROPRIATE DOSE OF NCX 470 TO BE ADVANCED INTO PHASE 3 CLINICAL STUDIES.

Nicox Receives A 3 Million Dollars Milestone Payment For Zerviate In The U.S.

July 9 (Reuters) - Nicox SA <NCOX.PA>::NICOX RECEIVES $3 MILLION MILESTONE PAYMENT FROM EYEVANCE FOR ZERVIATE IN THE U.S..EYEVANCE HAS INFORMED NICOX THAT LAUNCH IS CURRENTLY PROJECTED ANYTIME IN H1 2020 INSTEAD OF SUMMER THIS YEAR..NICOX REMAINS ELIGIBLE FOR UP TO $37.5 MILLION IN MILESTONES PAYABLE ON EYEVANCE ACHIEVING PRE-DEFINED SALES TARGETS.NICOX WILL ALSO RECEIVE TIERED ROYALTIES OF 8% TO 15% ON FUTURE NET SALES OF ZERVIATE IN U.S.ZERVIATE IS ALSO LICENSED TO OCUMENSION THERAPEUTICS FOR CHINESE MARKET, AND NICOX CURRENTLY RETAINS RIGHTS FOR ALL OTHER TERRITORIES OUTSIDE OF U.S. AND CHINA..

Nicox Signs Agreement For NCX 4251 In China With Ocumension Therapeutics

July 2 (Reuters) - NICOX SA <NCOX.PA>::NICOX SIGNS AGREEMENT FOR NCX 4251 IN CHINA WITH OCUMENSION THERAPEUTICS FOR UP TO €12 MILLION IN MILESTONES PLUS ROYALTIES.UPFRONT PAYMENT OF EUR 2 MILLION AND POTENTIAL FUTURE MILESTONES OF EUR 10 MILLION.WITH 3 PARTNERED PROGRAMS NICOX & OCUMENSION HAVE FORGED A STRONG PARTNERSHIP IN CHINA.TIERED ROYALTIES FROM 5% TO 10%.

Nicox Presents Update On NCX 470 Phase 2 Clinical Study

May 6 (Reuters) - NICOX SA <NCOX.PA>::DR. THOMAS WALTERS PRESENTS UPDATE ON NICOX’S NCX 470 PHASE 2 CLINICAL STUDY IN PODIUM PRESENTATION AT ASCRS 2019.ENROLLMENT RATE NOW AT 90%.PRESENTATION ALSO HIGHLIGHTED POTENTIAL FOR NCX 470 TO BECOME BEST-IN-CLASS FIRST LINE THERAPY FOR LOWERING INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION.TOP-LINE DATA IS EXPECTED IN Q4 OF THIS YEAR.

Nicox Q1 Net Revenue Up At 0.43 Million Euros

April 18 (Reuters) - NICOX SA <NCOX.PA>::REG-NICOX FIRST QUARTER 2019 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.THE TOTAL NUMBER OF PRESCRIPTIONS FOR VYZULTA IN THE U.S. IN THE FIRST QUARTER OF 2019 INCREASED BY 18% COMPARED TO Q4 20181 AND BY 360% COMPARED TO THE FIRST QUARTER 2018.AS OF MARCH 31, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €23.5 MILLION AS COMPARED WITH €22.0 MILLION AT DECEMBER 30, 2018.ENROLLMENT HAS NOW REACHED OVER 85% IN NCX 470 GLAUCOMA CLINICAL TRIAL, AND BOTH THIS AND NCX 4251 BLEPHARITIS TRIAL SHOULD GENERATE TOPLINE RESULTS IN Q4 OF THIS YEAR.NET REVENUE FOR THE FIRST QUARTER OF 2019 WAS €0.430 MILLION VERSUS €0.075 MILLION IN THE FIRST QUARTER OF 2018..WE EXPECT OUR RECURRENT REVENUES TO RAMP UP AS BAUSCH + LOMB PROGRESSES THE INTERNATIONAL ROLLOUT OF VYZULTA, AND WITH THE LAUNCH BY EYEVANCE OF ZERVIATE IN THE U.S - CEO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up